Health  Vol.4 No.12 , December 2012
Effective treatment of resistant Escherichia coli infection, with sulphadimidine stabilized in a synthetic Aluminium-Magnesium Silicate
ABSTRACT
To investigate if Aluminium-Magnesium Silicate (AMS) could make drugs regain effects against resistant pathogens, its effect was tested on sulphadimidine against sulphadimidine-resistant Escherichia coli. Two groups of chicks infected with sulphadimidine-resistant E. coli were treated at sulphadimidine dose rate of 1 g/litre of drinking water, with sulphadimidine and with an AMS-sulphadimidine drug formulation, respectively. Two other groups were similarly treated at sulphadimidine dose rate of 0.75 g/litre, while the fifth group served as control. Mean titres of the bacterium in bile of the chicks were compared. Titres, 119,200 ± 55,800 CFU/mL of the group treated with sulphadimidine at rate of 1 g/ litre and 14,800 ± 1700 CFU/mL of the group treated at rate of 0.75 g/litre, did not vary from 33,200 ± 5200 CFU/mL of the control (P > 0.05) but 295,200 ± 106,400 CFU/ml of the group treated at rate of 1 g/litre, with the AMS-sulpha- dimidine drug was significantly (P < 0.05) higher than that of the control while 5200 ± 1400 CFU/mL of the group treated at dose of 0.75 g/litre, with the AMS-sulphadimidine drug, reduced significantly (P < 0.05).

Cite this paper
Ezeibe, M. , Chima, U. , Ngene, A. , Okoroafor, O. , Kalu, I. and Esen, M. (2012) Effective treatment of resistant Escherichia coli infection, with sulphadimidine stabilized in a synthetic Aluminium-Magnesium Silicate. Health, 4, 1295-1298. doi: 10.4236/health.2012.412190.
References
[1]   NTP (1987) Abstract for Tr-318-Ampicillin Trihydrate (CASRN 7177-48-2) Toxicology and oarcinogenesis studies of Ampicillin Trihydrate (CAS No. 7177-48-2) in F344/N Rats and 36C 3F, Mice (Gavage studies), NTP Study Reports, National Toxicological Program, USA Government.

[2]   Ewers, C., Anto, E.M., Diehi, I., Philip, H.C. and Wieler, L.H. (2004) Molecular epidemiology of Avian pathogenic Escherichia coli isolated from colisepticaemia in poultry. Veterinary Microbiology, 104, 91-101. doi:10.1016/j.vetmic.2004.09.008

[3]   Johnson, J.R., Sannes, M.R., Croy, C., Johnson, B., Clabots, C., Kustowski, M.A., Bender, J., Smith, K.E., Winokur, P.L. and Belongia, E.A. (2007) Antimicrobial drug-resistant Esherichia coli from human and poultry products Minnesota and Wisconsin. Emerging Infectious Diseases, 13, 1576-1585. doi:10.3201/eid1306.061576

[4]   Butaye, P. and Jasson, V. (2000) E. coli infections: CODA -CERVA publications. www.coda-cerva.com

[5]   Murray, P.R. (2007) Mannual of clinical microbiology. 9th Edition, ASM Press, Washington.

[6]   McMullin, P. (2004) Poultry disease. www.poultrysite.com

[7]   Majowicz, S.E., Musto, J., Scallan, E., Angulo, F.J., Kir, K.M., O-Brien, S.J., Jones, T.F., Fazil, A. and Hoekkstra, R.M. (2010) The global burden of collibacillosis. Clinical Infectious Diseases, 50, 882-889. doi:10.1086/650733

[8]   Shane, S.M. (2009) Reducing pathogenic E. coli infection by vaccination. World Poultry, 25, 21-23.

[9]   Diarra, M.S., Silversides, F.G., Diarrasouba, F., Pritchard, J., Masson, L., Brouseau, R., Bonnet, C., Delaquis, P., Bach, S., Skura, B.J. and Topp, E. (2007) Impact of food supplementation with antimicrobial agents on growth performance of broiler chickens, Clostridium perfringes and enterococcus counts and antibiotic resistance phenotypes and distribution of antimicrobial resistance determinants in Escherichia coli isolates. Environmental Microbiology, 73, 6566-6576. doi:10.1128/AEM.01086-07

[10]   Brunton, L.L. (2006) The pharmacological basis of therapeutics. McGraw Hill, New York.

[11]   Craig, C.R. (1994) Mordern pharmacology with clinical applications. Lippincott Williams and Wilkins, New York.

[12]   Vanderbilt, R.T. (1992) Veegum—The versatile ingredient for pharmaceutical formulations, RT Vanderbilt Company, Inc., New York. www.rtvanderbilt.com

[13]   Cristina, E., Ivan, P. and Kevin, R. (2007) Nanomaterials and nanoparticles: Sources and toxicity. Biointerphases, 2, MR17-MR71. dol:10.1116/12815690.PMD.20419892

[14]   Smith, D.G. (1984) The Cambridge Encyclopedia of earth science. Cambridge University Press, London.

[15]   Wai, K., Dekay, H.G. and Banker, G.S. (1996) Application of Montmorillonite in tablet making. Journal of Pharmaceutical Sciences, 55, 1244-1248. doi:10.1002/jps.2600551116

[16]   Crowther, J. (1995) Advance Learners dictionary. Oxford University Press, New York.

[17]   Mineral Gallaries (2012) Zeolite Group www.galleries.com/zeolite.htm

[18]   Brent, W., Gunderson, Gigi, H., Ross, K.H.I. and John, C.R. (2001) What do we really know about antibiotics pharmacodynamics? Pharmacotherapy, 21, 28-31.

[19]   Ezeibe, M.C.O., Elendu-Eleke, N.P., Okoroafor, O.N. and Ngene, A.A. (2012) Adjuvant effect of a synthetic Aluminium-Magnesium Silicate on chloroquine phosphate, against Plasmodium berghei. Nature Precedings. http:hdt:10101/npre 201226749./posted 2 Jan 2012

[20]   Ezeibe, M.C.O., Anosa, G.N., Okorie, O.K., Elendu-Eleke, N.P., Okoroafor, O.N., Ngene, A.A. and Chikelu, O.N. (2012) Aluminium-Magnesium Silicate enhances antibacterial activity of Ampicillin trihydrate, against S. Gallinarum. Nature Preceding. http:hdt.handle.net/10101/npre.2012.6814.1.posted23Jan.2012

[21]   Ezeibe, M.C.O., Okafor, U.C., Okoroafor, O.N., Eze, J.I., Ngene, A.A., Animoke, P.C. and Mbuko, I.J. (2011) Effect of Aluminium-Magnesium Silicate on anticcocidial activity of sulphadimidine. Tropical Vet, 29, 41-44.

[22]   Ezeibe, M.C.O., Dire, C.D., Anosa, G.N., Chikelu, O.N., Okoroafor, O.N., Okorie, O.K., Ngene, A.A., Idika, I.K., Ogunniran, T.M. and Ezeala, I.E. (2012) Efficacy of Piperzine Citrate, stabilized with Aluminium-Magnesium Silicate, against Helignosomoides bakeri. Health, 4, 890- 892.

[23]   El-Mahmoudy, A., Mahmoud, M.E., Fararh, K., El-Magdoub, A. and Awidat, S. (2012) Sulphadimidine suppresses major histocompatibility complex expression in broiler chickens. British Journal of Pharmacology and Toxicology, 3, 2044-2046.

 
 
Top